HR Execs on the Move

Highfive Vet Wholesale

www.highfive.vet

 
Automated purchasing for vet clinics | Less mundane tasks. More time for your mission.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.highfive.vet
  • 1005, Terra Nova Boulevard
    Pacifica, CA USA 94044
  • Phone: 650.402.0109

Executives

Name Title Contact Details

Similar Companies

PharmaCord

PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years our team has provided support to millions of patients and driven commercial success for our client`s products. The leadership team of the company have led the launch of over 40 different products and transitioned dozens of programs spanning a 20-year period.

Meadow Lane Pharmacy

Meadow Lane Pharmacy is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Block Drug Company

Block Drug Company Inc. is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Servier Canada

Servier Canada is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Pharvaris

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.